Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Oculus Innovative Sciences — Corporate Update (June 2012)
5 slides from Sonoma Pharmaceuticals's corporate update, Jun 7, 2012
Slide 1: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
The Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This presentation includes forward - looking statements that are made pursuant to the “ safe harbor ” provisions of the Private Securities Litigation Reform Act of 1995 . while these statements are made to convey to
Slide 2: FY Expenses and Revenues
FY Expenses and Revenues 2 0.0 5.0 10.0 15.0 20.0 25.0 30.0 0.0 5.0 10.0 15.0 20.0 25.0 30.0 FY08 FY09 FY10 FY11 FY12 Expenses and Revenues ($M) Operating expense minus non-cash COGS minus non-cash Revenues Amneal/Quinnova Eloquest
Slide 3: Dermatology Units Sold through US Partners
3 Dermatology Units Sold through US Partners Trade Units Sold Projected
Slide 4: Partners and Clinical Strategy
Partners and Clinical Strategy 4 Partners SKU’ S Call Points Innovacyn 40+ Animal Health International 20+ Hospital and Pharmacies Amneal 3+ Derm RX Eloquest Healthcare 6 Hospital / Acute Care Onset Therapeutics 2 Derm RX Device Development Site Selection Clinical Study Top Line Data Reduction of Sc
Slide 5: Microcyn Scar Management Trial Design
Microcyn “Scar Management” Trial Design 5 A Double - blind, Randomized Study to Determine the Substantial Equivalence of Microcyn Scar Management Hydrogel, vs. Kelo - cote® Scar Gel for Management of Scars . Study Design: x 40 Adult subjects with Hypertrophic or Keloid Scars x 3x - daily dosing for
Oculus Innovative Sciences — Corporate Update (June 2012) on 6ix